Qian-Qian chen | Pharmacology | Best Researcher Award

Posted on by Pencis

Prof. Qian-Qian chen | Pharmacology | Best Researcher Award 

Prof. Qian-Qian chen, Nanjing University of Chinese Medicine, China

Prof. Qian-Qian Chen is an Associate Professor at the School of Pharmacy at Nanjing University of Chinese Medicine, China. He holds a Ph.D. in Pharmacognosy from China Pharmaceutical University, Nanjing. His research focuses on the molecular mechanisms of cardiovascular and renal diseases, the regulatory effects of traditional Chinese medicine (TCM) on disease progression, and the role of the neuraminidase protein family in chronic conditions. Prof. Chen has published extensively in high-impact journals such as Advanced Science, Nature Communications, and European Heart Journal. He is committed to advancing both modern pharmacology and TCM in the context of chronic diseases.

Author Profile

Orcid Profile

🎓EARLY ACADEMIC PURSUITS:

Prof. Qian-Qian Chen began his academic journey with a Bachelor of Science in Pharmacy from Beihua University, Jilin, China, graduating in June 2015. Demonstrating exceptional academic potential, he pursued a Master’s degree in Pharmacy at China Pharmaceutical University, Nanjing, China, from September 2015 to July 2018. He further refined his expertise by completing a Ph.D. in Pharmacognosy at the same university, achieving his doctorate in July 2021.

🏫PROFESSIONAL ENDEAVORS:

Currently serving as an Associate Professor and Master’s Supervisor in Pharmacology at the School of Pharmacy, Nanjing University of Chinese Medicine, Prof. Chen has been in this role since March 2022. His teaching and mentorship significantly contribute to nurturing the next generation of researchers in pharmacology and traditional Chinese medicine (TCM).

🔬CONTRIBUTIONS AND RESEARCH FOCUS ON Pharmacology:

Prof. Chen’s research is primarily centered around the molecular mechanisms underlying cardiovascular and renal diseases. His work focuses on three major areas:
1️⃣ Exploring the molecular pathways involved in cardiovascular and renal disease progression.
2️⃣ Investigating the regulatory effects of traditional Chinese medicine (TCM) on these diseases.
3️⃣ Unveiling the roles and mechanisms of the neuraminidase protein family in chronic conditions, including ventricular remodeling and chronic kidney injury.

His dedication to these fields has yielded a wealth of insights that advance understanding and treatment strategies for complex cardiorenal syndromes.

📈IMPACT AND INFLUENCE:

Prof. Chen has made significant contributions to the scientific community through his publications in prestigious journals. These include:

  • Advanced Science (2024)
  • Nature Communications (2023)
  • European Heart Journal (2021)
  • Journal of Ethnopharmacology (2021)
  • The American Journal of Chinese Medicine (2021)
  • Circulation (2018)

His groundbreaking studies on cardiovascular and renal diseases have been highly cited and praised for their clinical relevance and innovative methodologies.

📚ACADEMIC CITES AND LEGACY: 

Prof. Chen’s published work has been widely referenced in the fields of pharmacology, traditional Chinese medicine, and chronic disease research. His studies, particularly those addressing the interplay between cardiovascular and renal systems, serve as a cornerstone for researchers exploring related domains.

🌟FUTURE CONTRIBUTIONS AND VISION:

Looking ahead, Prof. Chen aims to:

  • Expand the understanding of traditional Chinese medicine’s regulatory roles in disease mechanisms.
  • Advance therapeutic strategies for chronic diseases through interdisciplinary research.
  • Mentor emerging researchers, fostering innovation and excellence in pharmacological sciences.

His commitment to merging modern scientific techniques with traditional medicine holds the promise of revolutionary breakthroughs in healthcare.

🌍CONCLUSION:

Prof. Qian-Qian Chen’s impressive academic trajectory, impactful research, and dedication to advancing pharmacology place him as a leading figure in his field. His work not only bridges the gap between traditional and modern medicine but also sets a foundation for transformative discoveries that will benefit patients worldwide.

Top Notable Publications:

Targeting Neuraminidase 4 Attenuates Kidney Fibrosis in Mice

Authors: Qian-Qian Chen

Journal: Advanced Science

Year: 2024

DOI: 10.1002/advs.202406936

Neuraminidase 1 is a Driver of Experimental Cardiac Hypertrophy

Authors: Qian-Qian Chen

Journal: European Heart Journal

Year: 2021

DOI: 10.1093/eurheartj/ehab347

Neuraminidase 1 and its Inhibitors from Chinese Herbal Medicines: An Emerging Role for Cardiovascular Diseases

Authors: Qian-Qian Chen

Journal: The American Journal of Chinese Medicine

Year: 2021

DOI: 10.1142/s0192415x21500403

PMID: 33827385

Untargeted Metabolomics and Lipidomics Uncovering the Cardioprotective Effects of Huanglian Jiedu Decoction on Pathological Cardiac Hypertrophy and Remodeling

Authors: Qian-Qian Chen

Journal: Journal of Ethnopharmacology

Year: 2020

DOI: 10.1016/j.jep.2020.113646

PMID: 33264659

Functional Metabolomics Characterizes a Key Role for N-Acetylneuraminic Acid in Coronary Artery Diseases

Authors: Qian-Qian Chen

Journal: Circulation

Year: 2017

DOI: 10.1161/circulationaha.117.031139

PMID: 29212895

Mincai li | vascular calcification | Best Researcher Award

Posted on by Pencis

Prof. Dr. Mincai li | vascular calcification | Best Researcher Award 

Prof. Dr. Mincai li, Hubei University of Science and Technology, China

Prof. Dr. Mincai Li is a distinguished academic at Hubei University of Science and Technology, China. He holds an MD and Master’s degree in Pathology and Pathophysiology from Huazhong University of Science and Technology. With extensive experience in teaching, Prof. Li has served as a Professor since 2017, after roles as Associate Professor and Lecturer at the same institution. His research focuses on the molecular mechanisms of atherosclerosis and the efficacy of glioma drugs. He has published over 40 scientific papers, including 15 SCI-indexed articles, and has received multiple awards for his scientific and teaching contributions.

Author Profile

Scopus Profile

🎓 Education Background:

Prof. Dr. Mincai Li completed his MD in Pathology and Pathophysiology at Huazhong University of Science and Technology (2007-2010), graduating in the top 10% of his class. He also earned his Master’s in Pathology and Pathophysiology from the same institution (2004-2007), ranking in the top 10%. Prior to that, he obtained a Bachelor’s in Clinical Medicine from Hubei University of Science and Technology (1993-1998), where he was in the top 30% of his cohort.

💼 Professional Experience:

Prof. Dr. Mincai Li has an extensive academic career at Hubei University of Science and Technology, where he has held progressively senior roles. Since January 2017, he has served as a Professor, following his tenure as Associate Professor from January 2012 to December 2016. From July 2010 to December 2011, he was a Lecturer, and earlier in his career, he worked as a Teaching Assistant from July 1998 to August 2004. Throughout his tenure, Prof. Dr. Li has contributed significantly to education and research in his field, shaping the academic environment at the university.

🩺 Medical Education & Teaching:

Prof. Dr. Mincai Li has made significant contributions to medical education, primarily teaching Pathology and Oral Histopathology courses. He has played a leading role in three provincial teaching research projects within Hubei’s higher education institutions, demonstrating his commitment to advancing academic standards. His exceptional teaching efforts have been recognized with awards, including a second prize and a third prize for teaching achievements at Hubei University of Science and Technology. Prof. Dr. Li’s dedication to both education and research has made a lasting impact on the academic community and the development of future medical professionals.

🔬 Scientific Research:

Prof. Dr. Mincai Li’s research primarily focuses on the molecular mechanisms of atherosclerosis and the efficacy of glioma drugs. He has led and contributed to 10 national, provincial, and municipal research projects, showcasing his expertise in these critical areas. Prof. Li has published over 40 scientific papers, including 15 SCI-indexed articles, and has edited a textbook. His significant contributions to scientific research have earned him recognition, including a second prize and a third prize for scientific and technological progress in Xianning City. His work continues to advance the understanding of critical medical conditions and therapeutic approaches.

🏅 Achievements and Honors:

Prof. Dr. Mincai Li has earned several prestigious awards throughout his career. In 2015, he was honored with the Second and Third Prizes for Science and Technology Progress in Xianning City, recognizing his contributions to scientific advancement. In 2016, he received both the Second and Third Prizes for Teaching Achievements at Hubei Institute of Science and Technology, highlighting his dedication to education. That same year, Prof. Li was awarded the Third Prize for the Second Natural Science Outstanding Academic Achievement Thesis Award in Xianning City, further acknowledging his impactful research and academic excellence. These accolades reflect his commitment to both teaching and scientific progress.

🌟Conclusion:

Prof. Dr. Mincai Li is a highly accomplished academic and researcher at Hubei University of Science and Technology, China. With a strong background in Pathology and Pathophysiology, he has made significant contributions to both education and scientific research. His work on atherosclerosis and glioma drugs has earned him national and regional recognition. As a dedicated professor, he has shaped the academic development of many students, while his research continues to advance medical science. Prof. Li’s numerous awards and honors reflect his unwavering commitment to excellence in both teaching and research.

Top Notable Publications:

Target analysis and identification of curcumin against vascular calcification

Authors: Li, Q., Zhou, Q., Li, S., Li, M., Xia, H.

Journal: Scientific Reports

Year: 2024

The causal relationship between thoracic aortic aneurysm and immune cells: a mendelian randomization study

Authors: Liu, G., Pan, S., Xia, H., Li, M., Wu, A.

Journal: BMC Cardiovascular Disorders

Year: 2024

Attenuating Atherosclerosis through Inhibition of the NF-κB/NLRP3/IL-1β Pathway-Mediated Pyroptosis in Vascular Smooth Muscle Cells (VSMCs)

Authors: Li, S., Li, Q., Zhou, Q., Liu, C., Li, M.

Journal: Cardiovascular Therapeutics

Year: 2024

Identification of key genes and pathways in atherosclerosis using integrated bioinformatics analysis

Authors: Li, S., Li, Q., Zhou, Q., Liu, C., Li, M.

Journal: BMC Medical Genomics

Year: 2023

Bioinformatic Identification of the Pyroptosis-Related Transcription Factor-MicroRNA-Target Gene Regulatory Network in Angiotensin II-Induced Cardiac Remodeling and Validation of Key Components

Authors: Huang, T., Ding, J., Lin, L., Yu, L., Li, M.

Journal: Frontiers in Bioscience (Landmark edition)

Year: 2023

Increased Neuromedin B is Associated with a Favorable Prognosis in Glioblastoma

Authors: Li, S., Li, Q., Zhou, Q., Liu, C., Li, M.

Journal: Frontiers in Bioscience – Landmark

Year: 2023

Study on mechanism of resveratrol regulation of NLRP3 mediated pyroptosis of vascular smooth muscle cells resistance to atherosclerosis

Authors: Li, S., Li, Q., Zhou, C., Ouyang, C., Li, M.

Journal: Drug Evaluation Research

Year: 2022

Curcumin suppresses glioblastoma cell proliferation by p-AKT/mTOR pathway and increases the PTEN expression

Authors: Wang, Z., Liu, F., Liao, W., Li, M., Xia, H.

Journal: Archives of Biochemistry and Biophysics

Year: 2020

Captopril Attenuates the Upregulated Connexin 43 Expression in Artery Calcification

Authors: Li, M., Wang, Z., Shao, J., Yu, L., Hu, Z.

Journal: Archives of Medical Research

Year: 2020